Efficacy and Safety of Efsubaglutide Alfa Injection 3 Mg Q2W in T2D Patients
Status:
NOT_YET_RECRUITING
Trial end date:
2026-03-31
Target enrollment:
Participant gender:
Summary
This study is a multicenter, randomized, open-label, active-controlled clinical trial with a two-period crossover design, aimed at evaluating the efficacy and safety of Efsubaglutide Alfa Injection 3 mg administered Q2W in patients with Type 2 Diabetes Mellitus (T2DM) who have inadequate glycemic control despite dietary and exercise interventions. The primary endpoint is time in range (TIR; glucose concentration 39-100 mmol/L) during the period from Week 6 to Week 8 of Efsubaglutide Alfa Injection treatment.